

1991 INDEX

A

Adenocarcinoma: of lung, Mar./Apr. 85-86

Alkaline phosphatase: placental, as tumor marker, Nov./Dec. 330-331

Allele losses: at multiple sites in lung cancer, Mar./Apr. 71

Alpha-fetoprotein elevation in various diseases, Nov./Dec. 314

in germ cell tumors, Nov./Dec. 316

screening results, Nov./Dec. 315

as tumor marker, Nov./Dec. 313-317

Antigen(s)

 cancer, mucinous-like, as tumor marker, Nov./Dec. 323-324

 carcinoembryonic (see Carcinoembryonic antigen)

 carcinoma, squamous cell, as tumor marker, Nov./Dec. 318

Lewis, and mucin-glycoprotein epitopes, Nov./Dec. 321

prostate specific, as tumor marker, Nov./Dec. 318-320

tissue polypeptide, as tumor marker, Nov./Dec. 317

Asbestos: and lung cancer, Mar./Apr. 68-69

Assays: of hormone receptor, comparison of, July/Aug. 172

B

B-cell lymphoma: after marrow transplant, Jan./Feb. 40-41

Beta-2-microglobulin: as tumor marker, Nov./Dec. 335-338

Biopsy: percutaneous fine-needle aspiration, in lung cancer, Mar./Apr. 82-83

Bone marrow (see Marrow)

Breast cancer-associated mucinous glycoproteins, Nov./Dec. 323-324

as tumor markers, Nov./Dec. 323-324

Breast cancer, early stage, July/Aug. 161-232

 abstract, July/Aug. 161-162

 chemotherapy of, adjuvant, July/Aug. 183-200

 drug regimen, optimal, July/Aug. 191-192

 duration of, optimal, July/Aug. 193-194

IBSCG Trial, July/Aug. 187

Intergroup Trial, July/Aug. 187-188

Milan Trial, July/Aug. 186-187

NSABP B-13 in, July/Aug. 188

regimens for, selection of, July/Aug. 194-195

single-agent vs. combination, July/Aug. 192-193

studies of, July/Aug. 183-188

toxicity of, July/Aug. 198-200

trials of, July/Aug. 184-185

chemotherapy, dose intensity, July/Aug. 188-190

DNA ploidy and, July/Aug. 176-178

endocrine treatment, July/Aug. 200-214

 historical perspective, July/Aug. 200-202

 new therapies, July/Aug. 213-214

genetic alterations in, July/Aug. 178-181

growth factor receptors in, July/Aug. 178-181

hormone

 receptor status, determination and significance, July/Aug. 170-174

 replacement, regulation and pregnancy in, July/Aug. 174-176

medical management, July/Aug. 161-232

Breast cancer (*cont.*)
multimodality treatment, sequencing of, July/Aug. 195-198
oncogenes in, July/Aug. 178-181
posttherapy evaluations, July/Aug. 214-215
prognostic factors, July/Aug. 162-183
application of, July/Aug. 181-183
histology in, July/Aug. 169-170
metastases extent in, July/Aug. 166-169
overview of, July/Aug. 182
proliferative fraction in, July/Aug. 176-178
recurrence in, local, July/Aug. 163-165
size of tumor in, July/Aug. 166-169
tamoxifen in, July/Aug. 202-207, 210-211
trials, July/Aug. 203

Breast cancer: marrow transplant in, Jan./Feb. 35-36

Bronchioloalveolar carcinoma
characteristics of, Mar./Apr. 76-77
pathology, Mar./Apr. 85-86

Bronchoscopy: fiberoptic, in lung cancer detection, Mar./Apr. 81-82

C

CA 15-3: as tumor marker, Nov./Dec. 322

CA 19-9: as tumor marker, Nov./Dec. 324-326

CA 50: as tumor marker, Nov./Dec. 324-326

CA 125: as tumor marker, Nov./Dec. 327-328

CA 195: as tumor marker, Nov./Dec. 326-327

Calcitonin: as tumor marker, Nov./Dec. 331

Cancer
antigen, mucinous-like, as tumor marker, Nov./Dec. 323-324

breast (see Breast cancer)
colon, CEA elevation in, Nov./Dec. 308

esophageal (see Esophagus, cancer)

gastric (see Gastric cancer)
gastrointestinal tract (see Gastrointestinal tract cancer)

hematological, marrow transplant in, Jan./Feb. 19-33

lung (see Lung cancer)

ovarian, marrow transplant in, Jan./Feb. 36

pancreas, CA 19-9 in, Nov./Dec. 325

testicular, marrow transplant in, Jan./Feb. 34-35

Carboplatin
in esophageal cancer, Sept./Oct. 259

in marrow transplant, Jan./Feb. 13

Carcinoembryonic antigen
concentrations in sera, Nov./Dec. 306
elevated
in colon cancer, Nov./Dec. 308
conditions associated with, Nov./Dec. 305

studies using, summary of, Nov./Dec. 310-311

as tumor marker, Nov./Dec. 304-313

Carcinogens: and lung cancer, Mar./Apr. 68-69

Carcinoma
bronchioloalveolar
characteristics, Mar./Apr. 76-77
pathology, Mar./Apr. 85-86

esophagus (see Esophagus, carcinoma)

lung (see Lung carcinoma)

squamous cell, antigen as tumor marker, Nov./Dec. 318

Catecholamines: as tumor marker, Nov./Dec. 333-334

Cell(s)
germ cell tumors, Nov./Dec. 316
stem (see Stem cells)

Cerebral metastasis: solitary, in lung cancer, May/June 117

Chemohormonal treatment: in breast cancer, July/Aug. 207-210

Chemotherapy

- in breast cancer (see Breast cancer, early stage, chemotherapy)
- of esophageal cancer (see under Esophagus, cancer)
- of esophageal carcinoma (see under Esophagus, carcinoma)
- of gastric cancer (see under Gastric cancer)
- in gastrointestinal tract cancer, upper, postoperative, Sept./Oct. 250
- in lung cancer (see Lung cancer, non-small cell, chemotherapy of)
- in marrow transplant (see Marrow transplant, chemotherapy)

Chest symptoms: in lung cancer, Mar./Apr. 75-77

Chromosome changes: in lung cancer, Mar./Apr. 71

Cisplatin-based regimens: in lung cancer, May/June 130-131

Colon: cancer, CEA elevation in, Nov./Dec. 308

Cranial radiotherapy: prophylactic, in lung cancer, May/June 126

Cryopreservation

- general principles, Jan./Feb. 10-11
- quality of, Jan./Feb. 10

Cyclophosphamide: in marrow transplant, Jan./Feb. 12-13

Cystitis: hemorrhagic, after marrow transplant, Jan./Feb. 44

Cytologic smears: of sputum, in lung cancer detection, Mar./Apr. 80

Cytomegalovirus: after marrow transplant, Jan./Feb. 39

Cytotoxic drugs: in marrow transplant, Jan./Feb. 12-14

D

Diet: and lung cancer, Mar./Apr. 69

DNA ploidy: in breast cancer, July/Aug. 176-178

Drugs: cytotoxic, in marrow transplant, Jan./Feb. 12-14

DuPAN-2: as tumor marker, Nov./Dec. 326

Dysphagia: in esophageal carcinoma, palliative techniques for, Sept./Oct. 267-268

E

EAP: in gastric cancer, Sept./Oct. 280

Epstein-Barr virus B-cell lymphoma after marrow transplant, Jan./Feb. 40-41

Endocrine

- dysfunction after marrow transplant, Jan./Feb. 44
- therapy in breast cancer (see Breast cancer, early stage, endocrine treatment)

Enolase: neuron specific, as tumor marker, Nov./Dec. 329

Enzyme markers: in oncology, Nov./Dec. 328-331

Esophagus, cancer

- carboplatin in, Sept./Oct. 259
- chemotherapy combination, Sept./Oct. 258
- single agent, Sept./Oct. 254-257
- definition of TNM, Sept./Oct. 243
- failure pattern, autopsy data, Sept./Oct. 246
- metastases, sites of, Sept./Oct. 246

Esophagus, carcinoma, Sept./Oct. 252-268

- chemotherapy, Sept./Oct. 253-260
- combination, Sept./Oct. 257-260
- drug regimen choice, Sept./Oct. 261
- with radiotherapy, Sept./Oct. 263-266
- surgery after, Sept./Oct. 261-263
- combined modality therapy, Sept./Oct. 261
- toxicities with, additive, Sept./Oct. 261
- dysphagia in, palliative techniques for, Sept./Oct. 267-268

Esophagus (cont.)

- interferon with fluorouracil in, Sept./Oct. 260
- Intergroup Trial, Sept./Oct. 266-268
- neoadjuvant therapy, Sept./Oct. 260-268
- radiotherapy of, Sept./Oct. 253 with chemotherapy, Sept./Oct. 263-266
- preoperative, Sept./Oct. 260-261
- response assessment, Sept./Oct. 254
- surgery, Sept./Oct. 252-253 with preoperative chemotherapy, Sept./Oct. 261-263
- treatment, Sept./Oct. 252-268

F

FAMTX: in gastric cancer, Sept./Oct. 281

α-Fetoprotein (see Alpha-fetoprotein)

Fiberoptic bronchoscopy: in lung cancer detection, Mar./Apr. 81-82

Fluorouracil: with interferon in esophageal carcinoma, Sept./Oct. 260

G

Gastric cancer, Sept./Oct. 268-282

- adjuvant therapy, Sept./Oct. 268-273
- advanced, Sept./Oct. 273-282
- chemotherapy, combination, Sept./Oct. 275-282
- chemotherapy of, single agent, Sept./Oct. 273-275
- chemotherapy, intraperitoneal, Sept./Oct. 271-273
- definition of TNM, Sept./Oct. 244
- EAP in, Sept./Oct. 280
- FAMTX in, Sept./Oct. 281
- metastases, sites of, Sept./Oct. 247

Gastrointestinal tract cancer, upper, Sept./Oct. 239-293

abstract, Sept./Oct. 239

H

adjuvant therapy

- choosing appropriate patient, Sept./Oct. 249-250
- postoperative, timing of, Sept./Oct. 252
- rationale for, Sept./Oct. 248-252
- site of primary, Sept./Oct. 248-249
- chemotherapy, postoperative, Sept./Oct. 250
- epidemiology, changing, 240-241
- failure pattern, Sept./Oct. 245-248
- prognostic variables, Sept./Oct. 243-245
- screening, Sept./Oct. 241-242
- staging, Sept./Oct. 242-243
- surgical procedure employed, type of, Sept./Oct. 250-252
- survival by stage, Sept./Oct. 251
- treatment, Sept./Oct. 239-293

Gene

- p53, abnormalities in lung cancer, Mar./Apr. 72
- rb, in lung cancer, Mar./Apr. 72

Genetic

- alterations in breast cancer, July/Aug. 178-181
- lesions in lung cancer, Mar./Apr. 69-74

Germ cell tumors, Nov./Dec. 316

Glycoprotein(s)

- mucin epitopes and Lewis antigens, Nov./Dec. 321
- mucinous, as tumor marker, Nov./Dec. 320-328
- tumor markers, Nov./Dec. 304-320

Gonadotropin, beta-human chorionic, Nov./Dec. 313-317

- in germ cell tumors, Nov./Dec. 316

Graft: hematopoietic stem cell, in marrow transplant, Jan./Feb. 9

Growth regulatory system: in lung cancer, Mar./Apr. 72-73

H

Hematological cancer: marrow transplant in, Jan./Feb. 19-33

Hematopoietic
reconstitution, methods, Jan./Feb. 7
stem cell (see Marrow transplant,
hematopoietic stem cell)

Hemorrhagic cystitis: after marrow
transplant, Jan./Feb. 44

Herpes simplex: after marrow trans-
plant, Jan./Feb. 38-39

Hodgkin's disease
marrow transplant in, Jan./Feb.
25-28
results, Jan./Feb. 23, 28

relapsed and refractory, condi-
tioning regimens for, Jan./
Feb. 26

Hormone(s)
in breast cancer (see Breast can-
cer, early stage, hormone in)
chemohormonal treatment in
breast cancer, July/Aug. 207-
210

receptor assays, comparison of,
July/Aug. 172

therapy in breast cancer, toxicity
of, July/Aug. 211-213

as tumor markers, Nov./Dec. 331-
334

I

Ifosfamide: in marrow transplant,
Jan./Feb. 13

Immune system molecules: as tu-
mor markers, Nov./Dec. 334-
338

Immunoglobulins: as tumor mark-
ers, Nov./Dec. 334-335

Interferon: with fluorouracil in
esophageal carcinoma, Sept./
Oct. 260

Irradiation (see Radiotherapy)

K

Kaplan-Meier survival curves: in
myeloma, Nov./Dec. 336

L

Lactic acid dehydrogenase: as tu-
mor marker, Nov./Dec. 330

Leukemia: marrow transplant in,
Jan./Feb. 28-32

Lewis antigens: and mucin-
glycoprotein epitopes, Nov./
Dec. 321

Liver toxicity: in marrow transplant,
Jan./Feb. 41-43

Lung
adenocarcinoma, Mar./Apr. 85-86
cancer (see below)
carcinoma
large cell, Mar./Apr. 86
squamous cell, Mar./Apr. 85
stem cells in lung cancer, Mar./
Apr. 84-85
toxicity and marrow transplant,
Jan./Feb. 41

Lung cancer, non-small cell, Mar./
Apr. 65-104, May/June 109-
154
abstract, Mar./Apr. 65-67
allele losses at multiple sites,
Mar./Apr. 71
asbestos and, Mar./Apr. 68-69
biopsy in, percutaneous fine-
needle aspiration, Mar./Apr.
82-83
bronchoscopy in, fiberoptic, Mar./
Apr. 81-82
carcinogens in, Mar./Apr. 68-69
chemotherapy, May/June 126,
127-142
administration principles, May/
June 128-134
combination, May/June 129-134
combination, cyclic alternating
May/June 132
dose-response relationships,
May/June 131-132
duration of, May/June 132-133
morbidity and mortality after,
May/June 134-135
perspective on, May/June 141-
142
preoperative, May/June 138-
139, 140
prognostic factors with, May/
June 133-134
with radiotherapy, May/June
137-138

Lung cancer (cont.)

- response assessment, May/June 128
- results, May/June 135-141
- selection of patients, May/June 127-128
- single-agent, May/June 128-129
- single agent, efficacy of, May/June 130
- with surgery, May/June 139-141
- survival and response in, May/June 133
- chest symptoms in, Mar/Apr. 75-77
- chromosomal changes in, Mar/Apr. 71
- cisplatin-based regimens in, efficacy, May/June 130-131
- clinical features, Mar/Apr. 74-78
- detection, early, Mar/Apr. 78-81
 - with biochemical markers, Mar/Apr. 80
- detection, immunohistochemical, from sputum cytologic smears, Mar/Apr. 80
- diagnosis, pathologic, Mar/Apr. 81-83
- diet and, Mar/Apr. 69
- etiology, Mar/Apr. 67-74
- genetic lesions in, Mar/Apr. 69-74
- growth regulatory system in, Mar/Apr. 72-73
- histologic types, frequency of, Mar/Apr. 84
- histopathologic events in, early, Mar/Apr. 84-85
- investigational approaches to tumor reduction, May/June 142-143
- metastases in
 - cerebral solitary, May/June 117
 - outside thorax, Mar/Apr. 77
- microscopic tumor at bronchial margin, resection results, May/June 117
- mutations in
 - number and timing, Mar/Apr. 73
- ras, Mar/Apr. 70

neuroendocrine features, Mar/Apr. 86

nicotine in, Mar/Apr. 72-73

occult

- identification of, Mar/Apr. 80-81
- resection results in, May/June 115

oncogenes in

- dominant, Mar/Apr. 70-71
- recessive, Mar/Apr. 71-74

operability determination, May/June 112-113

opioids in, Mar/Apr. 72-73

paraneoplastic syndromes in, Mar/Apr. 77

pathogenesis

- molecular, Mar/Apr. 69-74
- stages in, Mar/Apr. 84-85

pathology, Mar/Apr. 83-86

pericardial effusion in, Mar/Apr. 76

p53 gene abnormalities in, Mar/Apr. 72

pleural effusion in, malignant, Mar/Apr. 76

predisposition to, inherited, Mar/Apr. 73-74

prognostic factors, Mar/Apr. 86-92

radiotherapy in, May/June 118-127

- adjuvant, May/June 125-127
- with chemotherapy, May/June 137-138
- combination, contradictory effects of, May/June 134
- cranial, prophylactic, May/June 126
- definitive, May/June 118-125
- definitive, dose, May/June 120-121
- definitive, selection of patients, May/June 119
- definitive, survival effects of, May/June 123-124
- definitive, treatment volume, May/June 119-120

failure patterns, May/June 124-125

fractionation, May/June 120–122
 morbidity of, May/June 122
 palliative, May/June 126–127
 postoperative, May/June 125
 preoperative, May/June 125
 results, May/June 122–123
 in stage IV, May/June 126
 survival with, May/June 122–123
 techniques undergoing clinical evaluation, May/June 121–122
 radon and, Mar./Apr. 68–69
 rb gene in, Mar./Apr. 72
 resection results in, May/June 115–117
 screening for, Mar./Apr. 78–81
 clinical trials, Mar./Apr. 79–80
 smoking and, Mar./Apr. 68–69
 stage I
 radiotherapy results in, May/June 123
 resection results in, May/June 115
 stage II
 radiotherapy results, May/June 123
 resection results in, May/June 115
 stage IIIa, resection results in, May/June 116–117
 stage IV, radiotherapy and chemotherapy in, May/June 126
 staging, Mar./Apr. 86–92
 evaluation, Mar./Apr. 89–91
 techniques, Mar./Apr. 89–91
 TNM system, Mar./Apr. 87–88
 stem cells in, pulmonary, Mar./Apr. 84–85
 sulcus tumors, superior, May/June 123
 surgery of, May/June 112–118
 with chemotherapy, May/June 139–141
 failure patterns, May/June 117–118
 morbidity and mortality of, May/June 114–115
 procedures, May/June 113–114
 survival by stage, Mar./Apr. 83
 treatment, May/June 109–154
 abstract, May/June 109–111
 palliative, May/June 143–144
 vena cava syndrome in, superior, Mar./Apr. 76
 Lung cancer: small cell, marrow transplant in, Jan./Feb. 33
 Lymphoma
 Epstein-Barr virus B cell, after marrow transplant, Jan./Feb. 40–41
 marrow transplant in, Jan./Feb. 21–25
 results, Jan./Feb. 23

M

Malignancy (see Cancer)
 Marrow transplant, Jan./Feb. 5–57
 abstract, Jan./Feb. 5
 in breast cancer, Jan./Feb. 35–36
 carboplatin in, Jan./Feb. 13
 chemotherapy
 intensive, role of, Jan./Feb. 6–9
 single agent dose escalation, Jan./Feb. 8
 complications, Jan./Feb. 37–44
 cryopreservation in, Jan./Feb. 10–11
 cyclophosphamide in, Jan./Feb. 12–13
 cystitis after, hemorrhagic, Jan./Feb. 44
 cytomegalovirus after, Jan./Feb. 39
 cytotoxic drugs in, Jan./Feb. 12–14
 endocrine dysfunction after, Jan./Feb. 44
 engraftment
 delay in, Jan./Feb. 43
 effect of infections on, Jan./Feb. 40
 future directions, Jan./Feb. 44–46
 in hematological cancer, Jan./Feb. 19–33
 biological observations, Jan./Feb. 19–21
 hematopoietic engraftment in, Jan./Feb. 31

Marrow transplant (*cont.*)
hematopoietic stem cell(s)
 graft, Jan./Feb. 9
 storage, Jan./Feb. 9-11
herpes simplex after, Jan./Feb.
 38-39
high-dose therapy, principles of,
 Jan./Feb. 11-16
history, Jan./Feb. 5-9
in Hodgkin's disease, Jan./Feb.
 25-28
 results, Jan./Feb. 23, 28
ifosfamide in, Jan./Feb. 13
infections after, Jan./Feb. 37-41
in leukemia, Jan./Feb. 28-32
liver toxicity after, Jan./Feb. 41-43
in lung cancer, small cell, Jan./
 Feb. 33
in lymphoma, Jan./Feb. 21-25
 results, Jan./Feb. 23
lymphoma after, Epstein-Barr vi-
 rus B-cell, Jan./Feb. 40-41
melphalan in, Jan./Feb. 13-14
in neuroblastoma, Jan./Feb.
 33-34
in ovarian cancer, Jan./Feb. 36
purging in, Jan./Feb. 17-19
 methods, Jan./Feb. 18
radiotherapy and, Jan./Feb. 14-16
rationale, Jan./Feb. 5-6
in solid tumors, Jan./Feb. 33-36
in testicular cancer, Jan./Feb. 34-35
thiotepa in, Jan./Feb. 13
toxicity in
 lung, Jan./Feb. 41
 vascular, Jan./Feb. 43
Melphalan: in marrow transplant,
 Jan./Feb. 13-14
Metastases
 of breast cancer, July/Aug. 166-169
 cerebral metastasis, solitary, in
 lung cancer, May/June 117
 in esophageal cancer, sites, Sept./
 Oct. 246
 of gastric cancer, sites of, Sept./
 Oct. 247
 of lung cancer (see Lung cancer,
 metastases)
Model: of therapeutic outcome,
 Jan./Feb. 12

Morbidity in lung cancer
 with chemotherapy, May/June
 134-135
 radiotherapy, May/June 122
 surgery, May/June 114-115
Mortality in lung cancer
 with chemotherapy, May/June
 134-135
 surgery, May/June 114-115
Mucin-glycoprotein epitopes: and
 Lewis antigens, Nov./Dec. 321
Mutations (see Lung cancer, muta-
 tions in)
Myeloma: Kaplan-Meier survival
 curves in, Nov./Dec. 336

N

Neuroblastoma: marrow transplant
 in, Jan./Feb. 33-34
Neuroendocrine features: of lung
 cancer, Mar./Apr. 86
Neuron specific enolase: as tumor
 marker, Nov./Dec. 329
Nicotine: in lung cancer, Mar./Apr.
 72-73

O

Oncogenes
 in breast cancer, July/Aug. 178-
 181
 in lung cancer (see Lung cancer,
 non-small cell, oncogenes in)
Oncology, tumor markers in (see
 Tumor markers in oncology)
Opioids: in lung cancer, Mar./Apr.
 72-73
Outcome: therapeutic, model of,
 Jan./Feb. 12
Ovarian cancer: marrow transplant
 in, Jan./Feb. 36

P

Pancreas, cancer, CA 19-9 in, Nov./
 Dec. 325
Paraneoplastic syndromes: in non-
 small cell lung cancer, Mar./
 Apr. 77

Pericardial effusion: in lung cancer, Mar./Apr. 76

p53 gene: abnormalities in lung cancer, Mar./Apr. 72

Placental alkaline phosphatase: as tumor marker, Nov./Dec. 330-331

Pleural effusion: malignant, in lung cancer, Mar./Apr. 76

Pregnancy: during breast cancer, July/Aug. 174-176

Prostate acid phosphatase as tumor marker, Nov./Dec. 328-329 specific antigen as tumor marker, Nov./Dec. 318-320

R

Radiotherapy of esophageal carcinoma, Sept./Oct. 253 with chemotherapy, Sept./Oct. 263-266 preoperative, Sept./Oct. 260-261

of lung cancer (see Lung cancer, non-small cell, radiotherapy in) marrow transplant and, Jan./Feb. 14-16

Radon: and lung cancer, Mar./Apr. 68-69

ras mutations: in lung cancer, Mar./Apr. 70

rb gene: in lung cancer, Mar./Apr. 72

S

Smoking: and lung cancer, Mar./Apr. 68-69

Solid tumors: marrow transplant in, Jan./Feb. 33-36

Stem cells hematopoietic (see Marrow transplant hematopoietic stem cell)

of lung, in lung cancer, Mar./Apr. 84-85

Stomach (see Gastric)

T

Tamoxifen in breast cancer, July/Aug. 202-207, 210-211 trials, July/Aug. 203

Testicular cancer: marrow transplant in, Jan./Feb. 34-35

Therapeutic outcome: model of, Jan./Feb. 12

Thiotepa: in marrow transplant, Jan./Feb. 13

Thoracic symptoms: in lung cancer, Mar./Apr. 75-77

Thyroglobulin: as tumor marker, Nov./Dec. 331-333

Tissue polypeptide antigen: as tumor marker, Nov./Dec. 317

Toxicity of chemotherapy in breast cancer, July/Aug. 198-200

of hormonal therapy in breast cancer, July/Aug. 211-213

liver, after marrow transplant, Jan./Feb. 41-43

lung, in marrow transplant, Jan./Feb. 41

vascular, after marrow transplant, Jan./Feb. 43

Transplantation, marrow (see Marrow transplant)

Tumor(s)

germ cell, Nov./Dec. 316

markers in oncology (see below)

solid, marrow transplant in, Jan./Feb. 33-36

Tumor markers in oncology, Nov./Dec. 301-350

abstract, Nov./Dec. 301

alkaline phosphatase, placental, Nov./Dec. 330-331

alpha-fetoprotein, Nov./Dec. 313-317

beta-2-microglobulin, Nov./Dec. 335-338

CA 15-3, Nov./Dec. 322

CA 19-9, Nov./Dec. 324-326

CA 50, Nov./Dec. 324-326

CA 125, Nov./Dec. 327-328

CA 195, Nov./Dec. 326-327

calcitonin, Nov./Dec. 331

Tumor markers in oncology (cont.)

- cancer antigen, mucinous-like, Nov./Dec. 323-324
- carcinoembryonic antigen, Nov./Dec. 304-313
- carcinoma antigen, squamous cell, Nov./Dec. 318
- catecholamines, Nov./Dec. 333-334
- classification of, Nov./Dec. 302-303
- DuPAN-2, Nov./Dec. 326
- enolase, neuron-specific, Nov./Dec. 329
- enzyme, Nov./Dec. 328-331
- following treatment course, Nov./Dec. 338
- glycoprotein, Nov./Dec. 304-320
- mucinous, Nov./Dec. 320-328
- gonadotropin, beta-human chorionic, Nov./Dec. 313-317
- hormones, Nov./Dec. 331-334
- immune system molecules, Nov./Dec. 334-338
- immunoglobulins, Nov./Dec. 334-335
- lactic acid dehydrogenase, Nov./Dec. 330
- major, summary of, Nov./Dec. 337
- prostate specific antigen, Nov./Dec. 318-320
- prostactic acid phosphatase, Nov./Dec. 328-329
- thyroglobulin, Nov./Dec. 331-333
- tissue polypeptide antigen, Nov./Dec. 317
- use of, clinical, Nov./Dec. 301-350

V

Vena cava syndrome: superior, in lung cancer, Mar./Apr. 76

Vessels: toxicity after marrow transplant, Jan./Feb. 43

Viruses

- cytomegalovirus after marrow transplant, Jan./Feb. 39
- Epstein-Barr, B-cell lymphoma after marrow transplant, Jan./Feb. 40-41
- herpes simplex after marrow transplant, Jan./Feb. 38-39

v

Vena cava syndrome: superior, in lung cancer, Mar./Apr. 76
 Vessels: toxicity after marrow transplant, Jan./Feb. 43
 Viruses
 cytomegalovirus after marrow transplant, Jan./Feb. 39
 Epstein-Barr, B-cell lymphoma after marrow transplant, Jan. Feb. 40-41
 herpes simplex after marrow transplant, Jan./Feb. 38-39

